# INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.

> **NCT00615134** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 29 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** enfuvirtide [Fuzeon]
- **DRUG:** Optimized background ARV therapy

## Key facts

- **NCT ID:** NCT00615134
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2015-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00615134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00615134, "INNOVE Study: A Study of 3 Months Induction With Fuzeon (Enfuvirtide) + Optimized Background (OB) Versus OB Alone in HIV-1 Infected Patients With Virological Failure.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00615134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*